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Abstract 
Aripiprazole, a dopamine D2 receptor partial agonist, is used to treat 
schizophrenia. Although aripiprazole has been reported to protect non-dopaminergic 
neurons, its effect on dopaminergic neurons has yet to be investigated. In the present 
study, we examined whether aripiprazole protected dopaminergic neurons against 
glutamate-induced cytotoxicity in rat mesencephalic cultures. Pretreatment with 
aripiprazole protected dopaminergic neurons in a concentration-dependent manner. The 
neuroprotective effect was not attenuated by sulpiride, a dopamine D2 receptor 
antagonist, suggesting that the effect is  independent of dopamine D2 receptors. 
Aripiprazole reduced intracellular dopamine content in a concentration-dependent 
manner. In addition, its neuroprotective effect was partially inhibited when dopamine 
was added. These results suggest that aripiprazole protects dopaminergic neurons 
against glutamate cytotoxicity partly by reducing intracellular dopamine content. 
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Introduction 
Aripiprazole, a dopamine D 2 receptor partial agonist, has been used as an 
atypical antipsychotic [1, 10]. It has been reported that aripiprazole protected against 
kainic acid-induced striatal lesions by stimulating serotonin 5-HT1A receptors [3], 
inhibited excessive glutamate release in isolated nerve terminals ( synaptosomes) from 
the prefrontal cortex [23] and increased glutathione peroxidase activity in the cortex 
[5]. These reports suggest that aripiprazole is neuroprotective, although its effects on 
dopaminergic neurons have not been examined.  
Glutamate excitotoxicity has been implicated in several neurodegenerative 
processes, including ischemia and Parkinson ’s disease [2]. We previously found that 
excessive exposure to glutamate caused dopaminergic neuronal death in mesencephalic 
cultures [9, 20]. We also demonstrated that dopamine D2 receptor agonists had 
protective effects against the dopaminergic neurotoxicity [7, 21]. For example, 
bromocriptine protected mesencephalic neurons by scavenging free radicals via the 
stimulation of dopamine D2 receptors [21], while pramipexole, bromocriptine and 
7-OH-DPAT protected dopaminergic neurons by reducing intracellular dopamine 
content independently of dopamine D2 receptors [7]. Since aripiprazole also acts as an 
agonist at presynaptic dopamine D2 receptors [10], we examined whether aripiprazole 
has protective effects against glutamate-induced dopaminergic neurotoxicity in this 
study. We found that aripiprazole protected dopaminergic neurons against glutamate 
cytotoxicity in mesencephalic cultures by reducing intracellular dopamine content  
independently of dopamine D 2 receptors. 
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Materials and Methods 
Aripiprazole was kindly provided by Otsuka Pharmaceutical Co., Ltd. (Tokyo, 
Japan). Sulpiride was purchased from Sigma (St. Louis, MO). Dopamine was obtained 
from Nacalai Tesque (Kyoto, Japan).  GBR12909 was purchased from Tocris Cookson 
Ltd. (Bristol, UK). 
 Rat mesencephalic cultures were established according to methods described 
previously [9]. Briefly, the ventral two-thirds of the mesencephalon was dissected from 
rat embryos on the 16th day of gestation. The tissues were then chemically and 
mechanically dissociated into single cell suspensions. Cells were plated onto 0.1% 





were maintained in Eagle’s minimum essential medium (EMEM) containing 10% fetal 
calf serum [1-4 days in vitro  (DIV)] or horse serum [5-12 DIV]. Cultures were 
incubated at 37°C in a humidified atmosphere of 95% air and 5% CO 2. The animals 
were treated in accordance with the guidelines of the Kyoto University animal 
experimentation committee and of the Japanese Pharmacological Society.  
 For the evaluation of neurotoxicity, mesencephalic cultures were exposed to 
glutamate for 24 h at 9 DIV. Treated cultures were incubated in EMEM containing 10% 
horse serum without drugs for a further 48 h and fixed for immunocytochemistry. 
Following fixation with 4% paraformaldehyde for 30 min, they were incubated with 
0.2% Triton X-100 for 10 min. They were then incubated with anti-tyrosine 
hydroxylase (TH; Chemicon/Millipore, Temecula, CA) antibody for 2 h, with 
biotinylated secondary antibody for 1.5 h and with avidin -biotinylated horseradish 
peroxidase complex (Vector Laboratories Inc., Burlingame, CA) for 1.5 h. Finally, they 
were reacted with diaminobenzidine (Dojindo Laboratories, Kumamoto, Japan) 
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solution for 8 min. For the evaluation of viability, TH-immunoreactive cells were 
counted in 20 randomly selected fields (858×1287 m
2
/field). Counts were made by an 
observer blinded to the experimental treatments. The viability of neurons was 
calculated as a percentage of the number of sham-treated neurons. 
Intracellular dopamine content was measured by high performance liquid 
chromatography with electrochemical detection (HPLC-ED) as described previously 
[9]. Mesencephalic cultures were exposed to drugs at 8 DIV. To measure intracellular 
dopamine content after treatment with the drugs for 24 h, cells were scraped, 
centrifuged and resuspended in extraction buffer (200 L) (0.1 N perchloric acid 
containing 10 mM sodium disulfite and 1 mM EDTA). After sonication, the lysate was 
centrifuged at 17,000 g for 30 min. The supernatant (50 L) was analyzed by HPLC-ED. 
The intracellular dopamine content in sham-treated cells was expressed as 100%. The 
HPLC system consisted of an automatic sample injector (Model 231, Gilson, 
Villiers-le-Bel, France), a pump (EP-300, Eicom, Kyoto, Japan), a degasser (DG-300, 
Eicom), a reverse-phase column (Eicompak CA-5ODS, inner diameter: 2.1 mm, length: 
150 mm, Eicom), a column oven (ATC-300, Eicom) and an electrochemical detector 
(ECD-300, Eicom) with a working electrode versus an Ag/AgCl reference electrode. 
The working electrode was maintained at an oxidative potential of +750 mV. The 
mobile phase consisted of 0.1 M acetate-citrate buffer (pH 3.7) containing 300 mg/L 
sodium octylsulfate, 5 mg/L EDTA-2Na and 16% methanol, and the flow rate was set at 
0.23 mL/min. 
 The statistical significance of the difference among three or more groups of 
individual data was analyzed by the one-way analysis of variance (ANOVA) and post 
hoc multiple comparison using Tukey’s test. Statistical significance was defined as p < 
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0.05. Data were expressed as the mean ± S.E.M. 
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Results 
In agreement with our previous report [9], the exposure of mesencephalic 
cultures to glutamate (100 M) for 24 h at 9 DIV reduced the viability of dopaminergic 
neurons. The glutamate-induced dopaminergic neurotoxicity was significantly 
inhibited by pretreatment with aripiprazole (10 M) for 24 h and/or co-administration 
of aripiprazole (10 M) with glutamate (Fig. 1A). Since the pretreatment by itself was 
sufficient to protect dopaminergic neurons, it was chosen in subsequent experiments. 
Aripiprazole (10-30 M) showed the neuroprotective effect in a 
concentration-dependent manner (Fig. 1B), which was not suppressed by sulpiride, a 
dopamine D2 receptor antagonist (Fig. 1C).  
 We have reported that glutamate-induced dopaminergic neurotoxicity was 
mediated by intracellular dopamine [9]. To investigate the mechanism underlying the 
neuroprotective effect of aripiprazole, we examined intracellular dopamine content 
after treatment with aripiprazole for 24 h by HPLC-ED. Aripiprazole reduced 
intracellular dopamine content in a concentration-dependent manner (Fig. 2A). The 
reduction in intracellular dopamine content by treatment with aripiprazole (30 M) for 
24 h was not suppressed by co-administration of sulpiride (30 M) for 24 h, and a 
significant reduction was observed after treatment with aripiprazole for just 0.5 h (Fig. 
2B and C).  
 To confirm that the reduction in intracellular dopamine content contributes to 
the protective effect of aripiprazole  against glutamate cytotoxicity in dopaminergic 
neurons, dopamine (100 M) was applied for 3 h after 24-hour pretreatment with 
aripiprazole (30 M), and then the cultures were exposed to glutamate (100 M) in the 
presence of dopamine (100 M). The neuroprotective effect of aripiprazole against 
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glutamate cytotoxicity was significantly attenuated by the addition of dopamine, which 
was cancelled by GBR12909 (1 M), an inhibitor of dopamine transporter (Fig. 3).
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Discussion 
We found that aripiprazole, a dopamine D2 receptor partial agonist, protected 
dopaminergic neurons against glutamate cytotoxicity. We previously reported that 
dopamine D2 receptor agonists had protective effects against glutamate -induced 
dopaminergic neurotoxicity dependently or independently of dopamine D 2 receptors [7, 
21]. The neuroprotective effect of aripiprazole was not mediated by dopamine D2 
receptors because it was not suppressed by sulpiride. 
Endogenous dopamine affects the susceptibility of dopaminergic neurons to 
Pael receptor-, rotenone- and -synuclein-induced toxicity [11, 19, 24]. We also 
demonstrated that glutamate-induced dopaminergic neurotoxicity was mediated by 
intracellular dopamine [9]. In addition, dopamine D2 receptor agonists protected 
dopaminergic neurons against glutamate cytotoxicity by reducing intracellular 
dopamine content independently of dopamine D 2 receptors [7]. Aripiprazole also 
reduced intracellular dopamine content in a concentration -dependent manner and the 
neuroprotective effect of aripiprazole was attenuated by addi tion of dopamine. These 
results suggest that the protective effect is derived from the reduction in intracellular 
dopamine content.  
The neuroprotective effect was also seen when aripiprazole was administered 
together with glutamate, although the effect was smaller than that when it was 
administered before glutamate exposure. This result seems reasonable because the 
treatment with aripiprazole for 0.5 h significantly reduced intracellular dopa mine 
content but the reduction was smaller than that after treatment for 24 h. We have 
previously reported that dopamine receptor agonists and antagonists, including 
aripiprazole, reduced intracellular dopamine content by inhibiting vesicular 
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monoamine uptake in PC12 cells [8, 14]. Thus, it is likely that aripiprazole also 
reduced intracellular dopamine content by inhibiting vesicular monoamine uptake in 
mesencephalic cultures, although the mechanisms involved are not examined in the 
present study. The reduction of intracellular dopamine content by aripiprazole in 
mesencephalic cultures was observed at lower concentrations  than that by pramipexole, 
bromocriptine and 7-OH-DPAT [7]. It is suggested that aripiprazole inhibits vesicular 
monoamine uptake more potently than other dopamine receptor agonists . 
The protective effect of aripiprazole against glutamate-induced dopaminergic 
neurotoxicity was not fully suppressed when dopamine was added to the mesencephalic 
cultures, although intracellular dopamine content  was recovered by the addition of 
dopamine (data not shown). This result suggests that other mechanisms are also 
involved in the neuroprotection by aripiprazole. It has been reported that the 
neuroprotective effect of aripiprazole against kainic acid-induced striatal lesions in 
vivo was related to the activation of serotonin 5-HT1A receptors [3]. The mechanism 
underlying neuroprotection by stimulation of serotonin 5-HT1A receptors is still not 
fully understood but might involve neuronal hyperpolarization [15, 16]. Since 
serotonin 5-HT1A receptors are expressed in dopaminergic neurons of the ventral 
tegmental area [4], it is possible that the protective effect of aripiprazole against 
glutamate cytotoxicity in dopaminergic neurons is also brought by the stimulation of  
serotonin 5-HT1A receptors. In fact, it has been reported that 8-OH-DPAT, a serotonin 
5-HT1A receptor agonist, protected against NMDA-induced apoptotic cell death in  rat 
mesencephalic cultures and the neuroprotective effect was inhibited by a 5 -HT1A 
antagonist [13]. In addition, it has been reported that aripiprazole increased 
brain-derived neurotrophic factor (BDNF) levels and glutathione peroxidase activity [5, 
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17]. Therefore, it is possible that aripiprazole protects dopaminergic neurons against 
glutamate cytotoxicity not only by reducing intracellular dopamin e content but also by 
stimulating serotonin 5-HT1A receptors and increasing levels of neuroprotective factors. 
However, further experiments will be required to examine whether serotonin 5-HT1A 
receptors and these factors contribute to the protective effect  of aripiprazole on 
dopaminergic neurons. 
Some reports suggest that aripiprazole may be useful for reducing psychosis 
and improving mood and cognition in patients with Parkinson’s disease [6, 12, 22]. As 
glutamate cytotoxicity has been suggested to contribute to the continued degeneration 
of dopaminergic neurons in the progression of Parkinson ’s disease [18], aripiprazole 
may have the potential to inhibit dopaminergic neuronal degeneration in Parkinson ’s 
disease. 
In conclusion, aripiprazole protected dopaminergic neurons against glutamate 
cytotoxicity by reducing intracellular dopamine content. Our results provide a novel 
insight into the neuroprotective effect of aripiprazole on dopaminergic neurons.  
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Figure legends 
Figure 1 Effect of aripiprazole on glutamate cytotoxicity in dopaminergic neurons of 
mesencephalic cultures. (A) Aripiprazole (10 M) was applied for 24 h before and/or 
during exposure to glutamate (100 M) for 24 h. Co; co-administration of aripiprazole 
with glutamate for 24 h. Pre; pretreatment with aripiprazole for 24 h and exposure to 
glutamate for 24 h. Pre + Co; pretreatment with aripiprazole for 24 h and 
co-administration of aripiprazole with glutamate for 24 h. (B) After treatment with 
aripiprazole (10-30 M) for 24 h, cultures were exposed to glutamate (100 M) for 24 
h. (C) After treatment with aripiprazole (30 M) in the presence or absence of sulpiride 
(30 M) for 24 h, cells were exposed to glutamate (100 M) for 24 h. Data shown are 
mean values ± S.E.M. (n=8). ***p < 0.001, compared with sham. 
###
p < 0.001, 
compared with glutamate (100 M). n.s.; not significant. 
 
Figure 2 Effect of aripiprazole on intracellular dopamine content in mesencephalic 
cultures. (A) After treatment with aripiprazole (1 -30 M) for 24 h, intracellular 
dopamine content was determined by HPLC-ED. (B) After treatment with aripiprazole 
(30 M) in the presence or absence of sulpiride (30 M) for 24 h, intracellular 
dopamine content was determined by HPLC-ED. (C) After treatment with aripiprazole 
(30 M) for 0.5, 1 or 3 h, intracellular dopamine content was determined by HPLC-ED. 
Data shown are mean values ± S.E.M. (n=3).
 ###
p < 0.001, compared with sham. n.s. ; 
not significant. 
 
Figure 3 Effect of exogenous dopamine on aripiprazole -induced protection in 
dopaminergic neurons of mesencephalic cultures.  After treatment with aripiprazole (30 
 20 
M) for 24 h, dopamine (100 M) was applied for 3 h and then cultures were exposed 
to glutamate (100 M) in the presence of dopamine (100 M) for 24 h. GBR12909 (1 
M) was coadministered with dopamine (100 M). Data shown are mean values ± 
S.E.M. (n=8). ***p < 0.001, compared with sham. 
###
p < 0.001, compared with 
glutamate (100 M). n.s.; not significant. 
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